StockData

Scholar Rock vs Vor Biopharma

SRRK and VOR side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How SRRK and VOR compare

Scholar Rock is the larger company, worth 4.9 times as much as Vor Biopharma ($5.5B against $1.1B).

Vor Biopharma scores higher on the StockData Score (5 against 2 for Scholar Rock), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricSRRKVOR
Size and price
Market cap$5.5B$1.1B
Share price$45.08$18.18
Change, 1 year20.5%81.6%
Change, 5 years67.1%−92.4%
Beta (5Y)0.831.85
Employees28976
StockData Score
Total score25 (better)
Valuation score00
Growth score00
Performance score00
Health score25 (better)
Dividend score00
Valuation
P/B21.6×–
FCF yield−5.4% (better)−10.7%
Profitability
Return on equity−168%–
Financial health
Debt / equity0.77–
Interest coverage−38.0×–
Current ratio7.0213.50 (better)
Altman Z-score6.59 (better)−3.32
Piotroski F-score13 (better)
Dividends and buybacks
Buyback yield−4.6%–
Shareholder yield−4.6%0.00% (better)
Ownership
Held by institutions114%80.3%
Held by insiders28.9%–
Insider net buying, 12 months−$7.4M (better)−$49.4M
Short interest, % of float27.1%–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.